Patents Represented by Attorney David W. Evans

Find this attorney in the Justia Lawyer Directory

  • Human DNase
    Patent number: 6482626
    Abstract: This invention relates to a novel human deoxyribonuclease, referred to as LS-DNase, that is relatively resistant to inhibition by actin, as compared to human DNase I. The invention provides nucleic acid sequences encoding LS-DNase, thereby enabling the production of LS-DNase by recombinant DNA methods in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of LS-DNase.
    Type: Grant
    Filed: February 11, 2002
    Date of Patent: November 19, 2002
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Will F. Baron
  • Serine protease inhibitors
    Patent number: 6472393
    Abstract: Compounds having the structure shown below wherein A, B, N1, N2, X, Y, Q, R2, R5 and R6 are as defined herein are useful to inhibit serine protease enzymes, such as TF/factor VIIa factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.
    Type: Grant
    Filed: March 21, 2000
    Date of Patent: October 29, 2002
    Assignee: Genentech, Inc.
    Inventors: Ignacio Aliagas-Martin, Dean R. Artis, Michael S. Dina, John A. Flygare, Richard A. Goldsmith, Regina A. Munroe, Alan G. Olivero, Richard Pastor, Thomas E. Rawson, Kirk D. Robarge, Daniel P. Sutherlin, Kenneth J. Weese, Aihe Zhou, Yan Zhu
  • Tyrosine derivatives
    Patent number: 6469047
    Abstract: The compounds of the invention are inhibitors of alpha4 containing integrin-mediated binding to ligands such as VCAM-1 and MAdCAM.
    Type: Grant
    Filed: September 25, 2000
    Date of Patent: October 22, 2002
    Assignee: Genentech, Inc.
    Inventors: David Y. Jackson, Frederick C. Sailes, Daniel P. Sutherlin
  • Purified forms of DNase
    Patent number: 6440412
    Abstract: The present invention provides the identification and characterization of two components of a recombinant preparation of DNase. These components are the purified deamidated and non-deamidated human DNases. Taught herein are the separation of these components and the use of the non-deamidated species as a pharmaceutical per se, and in particular in compositions wherein the species is disclosed within a plastic vial, for use in administering to patients suffering from pulmonary distress.
    Type: Grant
    Filed: August 11, 2000
    Date of Patent: August 27, 2002
    Assignee: Genentech, Inc.
    Inventors: John Frenz, Steven J. Shire, Mary B. Sliwkowski
  • Amidine inhibitors of serine proteases
    Patent number: 6410733
    Abstract: Inhibitors of serine proteases are provided having formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein. In particular, the compounds bind to factor VIIa, tissue factor/factor Xa complex, thrombin, trypsin, plasmin and kallikrein and have anticoagulant activity. Pharmaceutical compositions comprising the compounds are useful for inhibiting the formation of veinous and/or arterial thrombi in vivo.
    Type: Grant
    Filed: September 5, 2001
    Date of Patent: June 25, 2002
    Assignee: Genentech, Inc.
    Inventors: Richard M. Pastor, Dean R. Artis, Alan G. Olivero
  • Human DNase I hyperactive variants
    Patent number: 6391607
    Abstract: The present invention relates to amino acid sequence variants of human DNase I that have increased DNA-hydrolytic activity. The invention provides nucleic acid sequences encoding such hyperactive variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of hyperactive variants of human DNase I.
    Type: Grant
    Filed: June 14, 1996
    Date of Patent: May 21, 2002
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Clark Qun Pan
  • Human DNase I variants
    Patent number: 6348343
    Abstract: The present invention relates to amino acid sequence variants of human DNase I that have reduced binding affinity for actin. The invention provides nucleic acid sequences encoding such actin-resistant variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of actin-resistant variants of human DNase I.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: February 19, 2002
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Steven Shak, Jana S. Ulmer
  • Human DNase II
    Patent number: 6265195
    Abstract: This invention relates to a novel human deoxyribonuclease, referred to as human DNase II. The invention provides nucleic acid sequences encoding human DNase II, thereby enabling the production of human DNase II by recombinant DNA methods in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and diagnostic and therapeutic uses of human DNase II.
    Type: Grant
    Filed: April 25, 1996
    Date of Patent: July 24, 2001
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, Will F. Baron